Tooling up for stem cell stocks
By on Mar 17, 2009 in Finances
Biotechs working on cell treatments seem poised to profit from President Obama’s decision to lift the ban on federal funding for embryonic stem cell research and the $15 billion in stimulus money marked for scientific research. But for investors, the best way to play the sector might be the companies that build the tools used by biotechs.
Original post by Technology news - Business 2.0 Magazine
You must be logged in to post a comment.